New drug shows promise for slowing kidney disease in alport syndrome
NCT ID NCT06425055
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called vonafexor in 26 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug is safe and if it can help protect kidney function. Participants took increasing doses over 24 weeks. The study is now complete, and results will show whether vonafexor might be a future treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vonafexor (also called EYP001a), an oral drug taken as a tablet once daily
What this could lead to
If it works, this could point toward a treatment to slow kidney decline in Alport syndrome, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a small, early proof-of-concept study with only 26 participants, so results may not apply to everyone. The drug may not improve kidney function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine
Los Angeles, California, 90095, United States
-
Dr Ankit Mehta - Renal Disease Research Institute
Dallas, Texas, 75126, United States
-
Dr Arnold Silva - Boise Kidney & Hypertension
Boise, Idaho, 83703, United States
-
Dr Eric Wallace - University of Alabama
Birmingham, Alabama, 35294, United States
-
Dr James Simon - Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dr Moglie Le Quintrec - Hopital Lapeyronie
Montpellier, 34090, France
-
Dr Suneel Udani - NANI Research
Hinsdale, Illinois, 60521, United States
-
Dr Tingting Li - Washington University
St Louis, Missouri, 63110, United States
-
Fundacio Puigvert
Barcelona, 08025, Spain
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Virgen de la Arrixaca
El Palmar, 30120, Spain
-
Pr Claire Rigothier - CHU De Bordeaux
Bordeaux, 33076, France
-
Pr. Bertrand Knebelmann - Necker Enfants Malades
Paris, 75015, France